News

Metformin reverses PKD
Enlarge image

ResearchItaly

Metformin reverses PKD

25.03.2013 - Italian researchers have tracked down the signalling pathway causing
polycystic kidney disease and identified a promising target.

Polycystic kidney disease (PKD) is one of the most common life-threatening genetic diseases, affecting an estimated 12.5 million people worldwide. Due
to multiple fluid-filled cysts, both kidneys enlarge and can also damage
liver, pancreas and - more rarely - heart and brain. Currently no treatment exists for the autosomally and recessively inherited forms of PKD.

The PKD-1 gene is mutated in 85% of the autosomal dominant form. Italian researchers have now found that the disorder can be targeted by an existing diabetes drug in combination with a glucose analogon. The team headed by Alessandra Boletta from San Raffaele Institute in Milan found that the PKD-1 mutation caused a switch in sugar metabolism towards aerobic glycolysis due to the inactivation of the master regulator AMPK (liver kinase B1-AMP activated protein kinase).

Forced activation of AMPK either by rapamycin, the diabetes medicine metformin or the non-metabolised sugar analogon 2-deoxy-glucose (2-DG) triggered reduction of the number of cysts in a mouse model. AMPK activation revitalized the ERK signalling pathway which re-activated mTORC1 that in turn normalised glycolysis. The researchers believe that a combination therapy of 2-DG and metformin offers a treatment opportunity for the progressive disease.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/metformin-reverses-genetic-kidney-diseas.html

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • PAION2.99 EUR11.15%
  • CO.DON3.00 EUR5.63%

FLOP

  • 4SC1.09 EUR-6.03%
  • STRATEC BIOMEDICAL39.80 EUR-3.40%
  • ADDEX3.22 CHF-3.30%

TOP

  • SANTHERA91.65 CHF43.0%
  • CO.DON3.00 EUR26.1%
  • PAION2.99 EUR20.1%

FLOP

  • EVOTEC3.07 EUR-18.1%
  • 4SC1.09 EUR-18.0%
  • MEDIGENE4.06 EUR-14.0%

TOP

  • SANTHERA91.65 CHF2202.8%
  • CO.DON3.00 EUR244.8%
  • PAION2.99 EUR190.3%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.58 EUR-41.1%
  • 4SC1.09 EUR-40.1%

No liability assumed, Date: 16.09.2014